Gianluca Svegliati Baroni
Marche Polytechnic University
Internal medicineEndocrinologyIntracellular pHSurgeryPathologyOncologyMolecular biologyHepatic stellate cellLiver cancerLiver diseaseCirrhosisCarcinomaHepatocellular carcinomaSorafenibLiver transplantationAngiogenesisFibrosisTransplantationHepatologyCancer researchCell growthMedicineBiologyGastroenterologyCell biology
Publications 72
#1Giovanni MarascoH-Index: 14
#2Francesco Poggioli (UNIBO: University of Bologna)
Last. Franco Trevisani (UNIBO: University of Bologna)H-Index: 49
view all 30 authors...
Among scores and staging systems used for HCC, none showed a good prognostic ability in patients with advanced HCC treated with Sorafenib. We aimed to evaluate predictive factors of overall survival (OS) and drug response in HCC patients undergoing Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Patients in the ITA.LI.CA database treated with Sorafenib and updated on 30 June 2019 were included. Demographic and clinical data before starting Sorafenib treatment were...
#1Giovanni Marasco (UNIBO: University of Bologna)H-Index: 14
#2Antonio ColecchiaH-Index: 42
Last. Franco Trevisani (UNIBO: University of Bologna)H-Index: 49
view all 30 authors...
BACKGROUND Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. AIMS To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. METHODS The performance of several prognostic scores was assessed through a Cox regression-model eva...
#1Luca Maroni (Marche Polytechnic University)H-Index: 14
#2Francesca Fianchi (UCSC: Catholic University of the Sacred Heart)H-Index: 1
Last. Gianluca Svegliati Baroni (Marche Polytechnic University)H-Index: 28
view all 4 authors...
Abstract The physiological functions of the liver and the intestine are intimately connected by tightly regulated mechanisms. The liver secretes bile acids in the intestine, which are fundamental in lipid digestion but also regulate the composition of the gut microbiota. In turn, the intestine regulates the synthesis of bile acids by a feedback loop based on the FXR/FGF-19 axis, and secretes in the blood stream a number of incretins that participate in glucose and lipid metabolism, at least in p...
Last. Marco VivarelliH-Index: 41
view all 3 authors...
#1Vincenzo Mazzaferro (University of Milan)H-Index: 89
#1Vincenzo Mazzaferro (University of Milan)H-Index: 4
Last. Carlo Sposito (University of Milan)H-Index: 7
view all 32 authors...
Summary Background Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. Methods We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian te...
16 CitationsSource
#1Luca Maroni (Marche Polytechnic University)H-Index: 14
#2C. Pinto (Marche Polytechnic University)H-Index: 6
Last. Marco Marzioni (Marche Polytechnic University)H-Index: 57
view all 19 authors...
: Disorders of the biliary tree develop and progress differently according to patient age. It is currently not known whether the aging process affects the response to injury of cholangiocytes. The aim of this study was to identify molecular pathways associated with cholangiocyte aging and to determine their effects in the biological response to injury of biliary cells. A panel of microRNAs (miRs) involved in aging processes was evaluated in cholangiocytes of young and old mice (2 months and 22 m...
4 CitationsSource
: The recurrence of HCV infection after liver transplantation was the main cause of mortality and loss of graft in transplanted patients until the use of direct-acting antivirals (DAAs). We performed a monocentric retrospective study from November 2014 to September 2017 at “Ospedali Riuniti”, Ancona, Italy, to evaluate the outcome and tolerability of DAAs after liver transplantation. In total, 55 patients with HCV recurrence after liver transplantation treated with DAAs were included. The most f...
#1Catia Giovannini (UNIBO: University of Bologna)H-Index: 19
#2Anna Maria Salzano (National Research Council)H-Index: 22
Last. Laura GramantieriH-Index: 41
view all 12 authors...
Sorafenib is the first targeted agent proven to improve survival of patients with advanced hepatocellular carcinoma (HCC) and it has been used in first line treatments with heterogeneous response across patients. Most of the promising agents evaluated in first-line or second-line phase III trials for HCC failed to improve patient survival. The absence of molecular characterisation, including the identification of pathways driving resistance might be responsible for these disappointing results. 2...
3 CitationsSource
#1Edoardo G. GianniniH-Index: 57
#2Laura BucciH-Index: 24
Last. Franco TrevisaniH-Index: 49
view all 30 authors...
The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS], macro-vascular invasion [MVI], extra-hepatic spread [EHS] or MVI+EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we...
47 CitationsSource
#1Edoardo G. GianniniH-Index: 57
Last. Franco TrevisaniH-Index: 49
view all 23 authors...